Focus on Pap smear test, HPV test, colposcopy, biopsy and endocervical curettage

0

Dublin, August 25, 2021 (GLOBE NEWSWIRE) – The report “Global Cervical Cancer Diagnostics Market Report 2021: COVID-19 Growth And Change By 2030” has been added ResearchAndMarkets.com to offer.

The global cervical cancer diagnostics market is forecast to grow from $ 7.227 billion in 2020 to $ 7.663 billion in 2021, with an average annual growth rate (CAGR) of 6%. The market is expected to reach $ 9.687 billion in 2025 at a CAGR of 6%.

The main players in the cervical cancer diagnostics market are Abbott Laboratories, Becton, Dickinson and Co., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche Ltd., Hologic Inc., QIAGEN NV, Quest Diagnostics Inc., Siemens Healthineers AG , Zilico and guided therapeutics.

The Cervical Cancer Diagnostic market consists of the sale of cervical cancer diagnostic equipment and related services by companies (organizations, sole proprietorships, and partnerships) that manufacture cervical cancer diagnostic equipment. Cervical cancer is a type of cancer that occurs in cells in the cervix. These devices are used to diagnose cervical cancer.

The increasing adoption of HPV home test kits is expected to be the new trend in the market. The at-home HPV test kits help women collect samples and conveniently get the results themselves without going to the laboratory for screening. As a result, companies focus on bringing comfort to patients.

The increased adoption of cervical cancer diagnostic tests for the early detection of cervical cancer is expected to fuel the cervical cancer diagnostic market. The increasing awareness of women about cervical cancer along with the emphasis by global cancer organizations and governments on early testing for the detection and prevention of cervical cancer is contributing to the growth of the market. The increasing adoption of diagnostic tests for cervical cancer and the emphasis on early detection are driving the market.

The increased use of HPV vaccination is expected to hamper the market for cervical cancer diagnostics. According to the World Health Organization, the two HPV types (16 and 18) cause 70% of cervical cancers and precancerous lesions of the cervix to develop into cervical cancer. The increased use of HPV vaccination is likely to hamper the market for cervical cancer diagnostics.

Key topics covered:

1. Summary

2. Market Characteristics for Cervical Cancer Diagnostics

3. Cervical Cancer Diagnostic Market Trends and Strategies

4. Effects of COVID-19 on the diagnosis of cervical cancer

5. Cervical Cancer Diagnostics market size and growth
5.1. Global Historical Cervical Cancer Diagnostic Market, 2015-2020, $ Billion
5.1.1. Driver of the market
5.1.2. Restrictions in the market
5.2. Global Cervical Cancer Diagnostic Prediction Market, 2020-2025F, 2030F, Billion US Dollars
5.2.1. Driver of the market
5.2.2. Restrictions in the market

6. Cervical Cancer Diagnostic Market Segmentation
6.1. Global Cervical Cancer Diagnostic Market, Segmentation By Diagnostic Tests, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

6.2. Global Cervical Cancer Diagnosis Market, Segmentation By End-User, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

6.3. Global Cervical Cancer Diagnostic Market, Segmentation By Age Group, History and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

  • Under 21

  • Age between 21 and 29

  • Age between 30 and 65

  • Over 65

7. Regional and country analysis of the Cervical Cancer Diagnostic Market
7.1. Global Cervical Cancer Diagnostic Market Split by Region, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars
7.2. Global Cervical Cancer Diagnostic Market Split by Countries, Historical and Forecast, 2015-2020, 2020-2025F, 2030F, Billion US Dollars

Mentioned companies

Please visit https://www.researchandmarkets.com/r/8kf4xy for more information on this report

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Source link

Share.

Comments are closed.